Raymond Debbane, Director at LEXICON PHARMACEUTICALS, INC. (LXRX), bought 202,425 shares at $2.25 ($487K) on 2019-09-13, disclosed to the SEC on 2019-09-17.
Open-market purchase of $487k LXRX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.25 | 200 | $450 | 0.1% |
| 2 | $2.27 | 400 | $908 | 0.2% |
| 3 | $2.28 | 300 | $684 | 0.1% |
| 4 | $2.29 | 300 | $687 | 0.1% |
| 5 | $2.30 | 800 | $2K | 0.4% |
| 6 | $2.31 | 500 |
| $1K |
| 0.2% |
| 7 | $2.32 | 2,309 | $5K | 1.1% |
| 8 | $2.33 | 1,300 | $3K | 0.6% |
| 9 | $2.34 | 1,101 | $3K | 0.5% |
| 10 | $2.35 | 1,700 | $4K | 0.8% |
| 11 | $2.35 | 200 | $471 | 0.1% |
| 12 | $2.36 | 2,068 | $5K | 1.0% |
| 13 | $2.36 | 200 | $472 | 0.1% |
| 14 | $2.37 | 5,494 | $13K | 2.7% |
| 15 | $2.38 | 400 | $950 | 0.2% |
| 16 | $2.38 | 400 | $952 | 0.2% |
| 17 | $2.38 | 28,225 | $67K | 13.8% |
| 18 | $2.39 | 21,652 | $52K | 10.6% |
| 19 | $2.40 | 1,200 | $3K | 0.6% |
| 20 | $2.40 | 152 | $365 | 0.1% |
| 21 | $2.40 | 34,087 | $82K | 16.8% |
| 22 | $2.40 | 152 | $365 | 0.1% |
| 23 | $2.40 | 1,200 | $3K | 0.6% |
| 24 | $2.41 | 24,772 | $60K | 12.3% |
| 25 | $2.42 | 200 | $483 | 0.1% |
| 26 | $2.42 | 15,582 | $38K | 7.7% |
| 27 | $2.42 | 200 | $484 | 0.1% |
| 28 | $2.42 | 900 | $2K | 0.4% |
| 29 | $2.43 | 900 | $2K | 0.4% |
| 30 | $2.43 | 18,051 | $44K | 9.0% |
| 31 | $2.44 | 1,700 | $4K | 0.9% |
| 32 | $2.44 | 1,700 | $4K | 0.9% |
| 33 | $2.44 | 29,880 | $73K | 15.0% |
| 34 | $2.44 | 100 | $244 | 0.1% |
| 35 | $2.45 | 3,800 | $9K | 1.9% |
| 36 | $2.45 | 100 | $245 | 0.1% |
| 37 | $2.46 | 100 | $246 | 0.1% |
| 38 | $2.46 | 100 | $246 | 0.1% |
| Total | $2.40 avg | 202,425 | $487K | 100% |
| Filing → |
| LXRX | BUY | 2026-02-23 | $220K | — | Filing → |
| LXRX | BUY | 2026-02-18 | $353K | — | Filing → |
| LXRX | BUY | 2023-10-12 | $2.2M | — | Filing → |